Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability & PK of Single Ascending Dose (Part 1) & an Open-label Assessment of Effect of Food on the PK (Part 2)

NCT01121302 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01121302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability & PK of Single Ascending Dose (Part 1) & an Open-label Assessment of Effect of Food on the PK (Part 2)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
December 31, 2010
Enrollment
88 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tolerability